Open Access

ARTICLE

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma

Qiuyun Luo^*†1, Wentao Pan^*†‡1, Suna Zhou^*†1, Guangfeng Wang^‡, Hanjie Yi^*§, Lin Zhang^*¶, Xianglei Yan^*†, Luping Yuan^*†, Zhenyi Liu^#, Jing Wang^**, Haibo Chen^#, MiaoZhen Qiu^*††, DaJun Yang^*†‡, Jian Sun^*‡‡

* State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, P.R. China
† Department of Experimental Research, Sun Yat-Sen University Cancer Center, Guangzhou, P.R. China
‡ Suzhou Ascentage Pharma Inc., Jiangsu, P.R. China
§ The Second Affiliated Hospital of Nanchang University, Nanchang, P.R. China
¶ University Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, Guangzhou, P.R. China
# Peking University Shenzhen Hospital, Shenzhen, P.R. China
** Guangzhou Red Cross Hospital, Guangzhou, P.R. China
†† Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, P.R. China
‡‡ Department of Clinical Research, Sun Yat-Sen University Cancer Center, Guangzhou, P.R. China